Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.

@article{ArellanoRodrigo2003SalvageTW,
  title={Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.},
  author={Eduardo Arellano-Rodrigo and Armando L{\'o}pez-Guillermo and Eric M. Bessell and Benet Nomdedeu and Emili Montserrat and Francesc Graus},
  journal={European journal of haematology},
  year={2003},
  volume={70 4},
  pages={219-24}
}
BACKGROUND Survival of patients with primary central nervous system lymphoma (PCNSL) has improved with methotrexate-based combination regimens and radiotherapy (RT). However, the prognosis of patients who fail or relapse after initial response is poor. Very little data is available on salvage treatment at recurrence. PATIENTS AND METHODS Sixteen immunocompetent patients (13 males/three females, median age 54 yr) with refractory (one patient) or recurrent (15 patients) PCNSL, homogeneously… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Similar Papers

Loading similar papers…